Fibromyalgia, Primary
Conditions
Keywords
balneotherapy
Brief summary
Balneotherapy (BT) is recommended as non-pharmacological treatment for Fibromyalgia Syndrome (FS). BT efficacy is based on beneficial properties of both mud bath and stay in a spa environment. The main aim of this multicentric prospective longitudinal cohort study is to evaluate BT effectiveness in patients withFS. All FS patients with a stable treatment in the past month and a Fibromyalgia Impact Questionnaire (FIQ) score ≥39 will be enrolled after providing written informed consent. Patients will be divided into two groups based on whether or not BT is added to usual therapy: BT Group and Control Group. Each patients will be assessed at baseline, after 15 and 45 days in BT Group and at baseline and after 15 days in Control group with an assessment of pain by Visual Analogue Scale, FIQ, Short-Form Health Survey, State-Trait Anxiety Inventory (STAI) and Center for Epidemiologic Studies Depression Scale (CES-D). Collected data will provide a new insight of BT role and the removal of daily stress in FS management
Interventions
PROCEDUREBalneotherapy
The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks. The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica.
Sponsors
Azienda Ospedaliera Universitaria Senese
University of Siena
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of primary FS according to the 2010 American College of Rheumatology (ACR) criteria; * Pharmacological and non pharmacological treatment stable for at least 3 months; * FIQ-Total score ≥ 39
Exclusion criteria
* Secondary FS; * Primary FS patients actually enrolled in other clinical trials; * Patients who had receveid a cycle of BT or of mud-bath in the previous 6 months; * Patients treated with intra-articular steroid injections of any joints in the previous 3 months; * Pregnancy or breastfeeding; * Cognitive or psychiatric disorders and history of substance abuse; * Absolute and relative contraindications to BT
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Minimal Clinically Important Difference (MCID) | 15 days | Percentage of patients achieving MCDI, defined as a reduction\>14% of FIQ-total score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fibromyalgia Impact Questionnaire (FIQ) | basal time;15 days;45 days | FIQ is an extensively validated patient self-report questionnaire, evaluating the impact of FS on daily life. In this study, we will use the Italian version of the FIQ. It ranges from 0 to 100, with higher scores indicating greater impact of FS on functioning. |
| Short-Form Health Survey (SF-12) | basal time;15 days;45 days | The 12-item SF-12 is a short version of SF-36 that is a widely used measure of health and well-being, validated in multiple countries, including Italy. SF-12 comprises two main domains: the physical component score (PCS) and the mental component score (MCS), and eight scales for assessing eight dimensions: physical functioning, physical role, social role, emotional role, bodily pain, general health, vitality, and mental health. Scores range from 0 to 100 where 0 indicates the worst condition and 100 indicates the best possible condition. |
| Visual Analogue Scale (VAS) | basal time;15 days;45 days | Assessment of pain on a 0-10-cm Visual Analogue Scale (VAS) with 0 = no pain and 10 = the worst pain possible |
| Center for Epidemiologic Studies Depression Scale (CES-D) | basal time;15 days;45 days | The 20-item CES-D Scale is frequently used to estimate the prevalence of depressive symptomatology in the general population. Respondents rate the frequency with which they have experienced particular depressive symptoms during the past week. Responses to each item range from 0 (less than 1 day) to 3 (5-7 days) and are summed to compute a total score. The Italian version measures one depression factor scoring from 0 to 60; scores of 16 or above are considered cases of depression. |
| Adverse events | 15 days | Percentage of patients reporting adverse events |
| State-Trait Anxiety Inventory (STAI) | basal time;15 days;45 days | STAI is a self-report questionnaire with two independent 20-item scales (STAI T-Anxiety Scale or Form X-2 and STAI S-Anxiety Scale or Form X-1) for measuring state-related or trait-related anxiety. A high score on the STAI corresponds to a high level of anxiety symptoms. We will use the Italian validated version. |
Countries
Italy
Contacts
Primary ContactAntonella Fioravanti
Outcome results
None listed